149P KEYNOTE-629: Efficacy of pembrolizumab (Pembro) per immune-related RECIST (irRECIST) in locally advanced (LA) and recurrent or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC)
Abstract:19del, and 14 pts (43.8%) with exon 21 L858R. 17 pts (53.1 %) had progression on both 1 st /2 nd and 3 rd EGFR-TKIs treatment. 10 pts (31.3%) had prior anti-angiogenesis treatment. The ORR and DCR were 59.4% (95%CI 40.6-76.3) and 90.6% (95%CI 75.0-98.0), respectively. Median TTR was 80 (41-93) days. Favorable ORR was observed in all subgroups (Table ). Among 40 pts, TEAE occurred in 37 pts (92.5%), and grade 3 TEAE occurred in 13 pts (32.5%). Most common TRAE (>25%) included leukopenia, neutropenia, anemia, th… Show more
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.